The biopharmaceutical industry is a strategic emerging industry that is encouraged and developed by the country and our province. Based on a distinctive industrial foundation, our city has identified medical devices and biopharmaceuticals as one of the eight key industrial chains for development. From January to June, the invoiced sales of this industrial chain increased by 26.2% year-on-year, and the investment in 12 key projects on the chain was completed by 81%.

At present, the medical device and biopharmaceutical industry chain in our city has preliminarily formed an industrial development trend with medical devices as the main component and biopharmaceutical as the supplement. The medical equipment industry is mainly concentrated in the midstream product manufacturing fields such as diagnostic and therapeutic equipment, rehabilitation nursing equipment, and medical auxiliary consumption. It has a group of backbone enterprises such as Yuyue Medical (34.850, -0.46, -1.30%), Dongfang Biological (37.780, -0.33, -0.87%) projects. Among them, Yuyue Medical Oxygen concentrator, electronic Sphygmomanometer, Glucose meter and other major products have maintained good growth. The medical Oxygen concentrator has achieved 65% of the domestic market share and 46% of the international market share; The products of the pharmaceutical industry chain are concentrated in the fields of traditional Chinese medicine (medicinal herbs) production, chemical medicine production, biopharmaceuticals, pharmaceutical excipients, etc. Among them, Kingsray holds a global leading position in the field of key underlying technology gene synthesis in life sciences. Gilbert (35.650, 0.45, 1.28%) products cover multiple treatment fields such as improving white blood cells, enhancing immunity, treating joint diseases, anti hypertension, and anti eye infections. Huahong Pharmaceutical has the pre-treatment of traditional Chinese medicine slices There are multiple production lines for packaging traditional Chinese medicine slices, with over 500 varieties produced and an annual production capacity of 6000 tons.

It can be said that the industrial chain has obvious characteristics and has certain advantages in project support, cluster effect, development potential, and other aspects. "Liu Lizhao, Director of the Service Industry Department of the Municipal Development and Reform Commission and member of the Industrial Chain Leader's Office, analyzed the current situation of the industrial chain. From the perspective of project support, in recent years, a number of large-scale and strong driving projects have emerged in our city. Yuyue Medical relies on its newly built intelligent factory to rapidly expand, Jinsirui builds a new production base, and Chinese medicine Danyang builds logistics and warehousing bases and Gaoduan Kangfu Medical Equipment Base in batches. This year, the city plans to invest 3.7 billion yuan in 12 key projects in the medical device and biopharmaceutical industry chain, with a total investment of 2.97 billion yuan completed in the first half of the year.

A batch of major projects have been smoothly promoted, laying the foundation for the accelerated development of the industrial chain. The industrial cluster effect is prominent, providing more support for the extension of the upstream and downstream of the industrial chain and enhancing its competitiveness. At present, the medical device and biopharmaceutical industry chain in our city is mainly concentrated in two sectors: Danyang and Zhenjiang New Area. From the distribution of 68 above designated enterprises, there are 33 in Danyang and 15 in Zhenjiang New Area, accounting for 71% of the total number of above designated enterprises. Industrial agglomeration further promotes the agglomeration of various factors such as talent and resources, accelerates innovation in new processes and technologies, and continuously promotes industrial upgrading.

It is worth mentioning that during this process, the Municipal Development and Reform Commission, as the leading department of the industrial chain, fully played a coordinating and promoting role, favoring major projects and high-quality enterprises in terms of land use, energy use, environment, finance, human resources, etc., to ensure the smooth progress of the projects and the early production and effectiveness.

From a policy perspective, the development potential of the industrial chain is enormous. In recent years, China has continuously issued a series of policy guidance opinions closely related to the life and health industry, vigorously promoting the development of the life and health industry from the top-level design level. "Tan Qinlei, director of the Municipal Development and Reform Commission, analyzed that not only that, but also the public's health awareness continues to improve, creating broad space for the development of the medical equipment and biopharmaceutical industry chain. The development and reform department comprehensively sorted out the missing links in the industrial chain, implemented full lifecycle management to address the problems in industrial scale, high-end products, supporting industries, and other aspects, strengthened supply chain, extension chain, and strengthening chain, and accelerated the improvement of the level and competitiveness of the industrial chain

In particular, in terms of accelerating the attraction of high-quality projects, our city gives full play to the existing industrial foundation advantages of Danyang Life Health Industrial Park, Zhenjiang New District Regenerative medicine Town, etc., launches industrial investment, cluster investment, strategic investment around the industrial chain, aims at the weak points, weak links and key links of the industrial chain, and strives to introduce a batch of high-quality projects with high industrial level, excellent technology and strong driving ability Key enterprises and research and development centers have settled down.

Our city will also rely on the Pharmaceutical Quality Management Association, lead by leading backbone enterprises, collaborate with upstream and downstream enterprises, relevant universities, and research institutions in the industrial chain to build a medical device and biopharmaceutical industry chain alliance, strengthen resource integration and optimization restructuring, and promote the high-quality development of the medical device and biopharmaceutical industry chain.

。